SCHEMBL2176967

SCHEMBL2176967

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)Nc4ccc(F)c(F)c4)cc3)cc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSGALNACT1 Q8TDX6 1/20 0.43
LMNA P02545 2/20 0.43
TP53 P04637 1/20 0.43
KDR P35968 2/20 0.42
EPHB4 P54760 2/20 0.42
TEK Q02763 2/20 0.42
EGFR P00533 1/20 0.42
PDGFRB P09619 1/20 0.42
KIT P10721 1/20 0.42
FGFR1 P11362 1/20 0.42
FLT1 P17948 1/20 0.42
SDCBP O00560 7/20 0.41
SDC2 P34741 7/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
KCNJ6 P48051 1/20 0.39
KCNJ5 P48544 1/20 0.39
KCNJ3 P48549 1/20 0.39
DGAT1 O75907 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179349 1.00 CSGALNACT1 (0.43) CSGALNACT1LMNATP53KDREPHB4
SCHEMBL13719256 0.93 LMNA (0.44) CSGALNACT1LMNATP53KDRSDCBP
SCHEMBL2179818 0.93 LMNA (0.44) CSGALNACT1LMNATP53KDRSDCBP
SCHEMBL2181411 0.92 SDCBP (0.48) CSGALNACT1LMNATP53KDREPHB4
SCHEMBL2180320 0.92 SDCBP (0.48) CSGALNACT1LMNATP53KDREPHB4
SCHEMBL2181198 0.91 LMNA (0.47) CSGALNACT1LMNATP53EGFRSDCBP
SCHEMBL2182061 0.91 LMNA (0.47) CSGALNACT1LMNATP53EGFRSDCBP
SCHEMBL2178892 0.89 LMNA (0.43) CSGALNACT1LMNATP53KDREGFR
SCHEMBL2178898 0.89 LMNA (0.43) CSGALNACT1LMNATP53KDREGFR
SCHEMBL2179283 0.89 LMNA (0.51) LMNATP53KDREGFRSDCBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT CSGALNACT1 783/4885LMNA 2193/4885TP53 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.